DOC vs OHI vs AHR
161 measures in 16 categories, one definition each, computed from filings and market data.
DOC41.2
Healthpeak Properties, Inc.
Real Estate · REIT - Healthcare Facilities
$18.98 +0.11%$13.1B mkt cap
Score DNA
OHI69.5
Omega Healthcare Investors, Inc.
Real Estate · REIT - Healthcare Facilities
$45.64 +0.26%$13.8B mkt cap
Score DNA
AHR62.2
American Healthcare REIT, Inc.
Real Estate · REIT - Healthcare Facilities
$53.23 +0.43%$11.6B mkt cap
Score DNA
Price, rebased to 100 three years ago
DOC OHI AHR · weekly adjusted closesSmart money 8Valuation 16Profitability (TTM) 12Returns on capital 11Growth 17Margin history & stability 7Liquidity (latest quarter) 7Leverage & solvency (latest quarter) 13Efficiency 11Cash flow & earnings quality 7Dividends & buybacks 9Scores & forensic checks 15Per share 7Size (TTM) 8Price performance 9Technicals 4
● marks the highest or lowest value where that direction is plainly stronger (margins, returns, coverage, leverage); multiples and yields are left unmarked. Bars show each stock's percentile within its own industry. n/a: the measure does not apply to lenders and insurers.
Smart money
8 measures| Measure | DOC | OHI | AHR |
|---|---|---|---|
| Insider open-market buys, 180d | 0 | 0 | 0 |
| Insider $ bought, 180d | — | — | — |
| Congress purchases, 180d | 0 | 0 | 0 |
| Last Congress purchase | — | — | — |
| 13F net change in holders | — | +19 | +56 |
| ETFs adding shares, 30d | 611 | 421 | 351 |
| ETFs trimming, 30d | 473 | 285 | 213 |
| Net ETF funds, 30d | +138 | +136 | +138 |
Valuation
16 measures| Measure | DOC | OHI | AHR |
|---|---|---|---|
| P/E (TTM) | 51.6x
58th
|
16.1x
8th
|
95.7x
83rd
|
| PEG (P/E ÷ 3-yr EPS CAGR) | — | 0.40
14th
|
— |
| Price / sales | 4.4x
38th
|
10.7x
88th
|
4.6x
44th
|
| Price / book | 1.7x
44th
|
2.6x
75th
|
3.1x
88th
|
| Price / tangible book | 2.1x
36th
|
3.2x
79th
|
3.1x
71st
|
| Price / free cash flow | 44.2x
73rd
|
15.3x
36th
|
44.2x
82nd
|
| Price / operating cash flow | 10.6x
8th
|
15.5x
54th
|
31.4x
85th
|
| Enterprise value | $21.8B
88th
|
$17.8B
81st
|
$13.0B
75th
|
| EV / sales | 7.4x
31st
|
13.8x
81st
|
5.2x
19th
|
| EV / EBITDA | 12.2x
12th
|
12.3x
19th
|
31.1x
94th
|
| EV / EBIT | 31.8x
54th
|
15.9x
8th
|
83.4x
92nd
|
| EV / free cash flow | 73.5x
82nd
|
19.7x
27th
|
49.6x
64th
|
| Earnings yield | 1.9%
56th
|
6.2%
94th
|
1.0%
38th
|
| FCF yield | 2.3%
50th
|
6.5%
75th
|
2.3%
44th
|
| Operating cash flow yield | 9.4%
94th
|
6.4%
56th
|
3.2%
31st
|
| Graham number (per share) | $9.70
17th
|
$32.26
67th
|
$16.63
33rd
|
Profitability (TTM)
12 measures| Measure | DOC | OHI | AHR |
|---|---|---|---|
| Gross margin | 2.5%
31st
|
72.0%
81st
|
14.9%
38th
|
| EBITDA margin | 60.4%
64th
|
— | 16.7%
21st
|
| Operating margin | 17.6%
44th
|
62.4%
94th
|
6.7%
25th
|
| EBIT margin | 23.2%
53rd
|
86.5%
100th
|
6.2%
27th
|
| Net margin | 8.6%
50th
|
66.4%
94th
|
4.8%
31st
|
| NOPAT margin | 17.4%
47th
|
61.3%
93rd
|
8.4%
27th
|
| FCF margin | 10.0%
38th
|
69.9%
94th
|
10.5%
44th
|
| Operating cash flow margin | 41.7%
62nd
|
68.9%
94th
|
14.7%
25th
|
| R&D / revenue | 0.0%
0th
|
0.0%
0th
|
0.0%
0th
|
| SG&A / revenue | 3.1%
40th
|
5.0%
53rd
|
1,500.4%
100th
|
| Stock comp / revenue | 0.8%
33rd
|
4.1%
87th
|
0.8%
40th
|
| Effective tax rate | 1.3%
47th
|
1.8%
53rd
|
-24.4%
0th
|
Returns on capital
11 measures| Measure | DOC | OHI | AHR |
|---|---|---|---|
| ROE (on average equity) | 3.2%
44th
|
16.5%
100th
|
4.0%
56th
|
| ROA | 1.2%
44th
|
8.3%
100th
|
2.4%
62nd
|
| ROIC | 3.1%
44th
|
8.4%
94th
|
4.1%
56th
|
| ROCE | 3.3%
44th
|
11.5%
100th
|
3.2%
38th
|
| Return on tangible assets | 3.3%
44th
|
10.9%
100th
|
3.1%
38th
|
| Cash ROIC (OCF / invested capital) | 7.4%
75th
|
9.5%
100th
|
7.2%
69th
|
| Gross profitability (GP / assets) | 0.3%
31st
|
9.3%
88th
|
4.4%
50th
|
| ROIC, 3-yr average | 2.1%
57th
|
5.6%
79th
|
1.0%
29th
|
| ROIC, 5-yr average | 2.8%
62nd
|
4.9%
85th
|
— |
| ROE, 5-yr average | 4.1%
62nd
|
10.6%
92nd
|
— |
| Incremental ROIC | 39.5%
93rd
|
-56.8%
7th
|
22.3%
79th
|
Growth
17 measures| Measure | DOC | OHI | AHR |
|---|---|---|---|
| Revenue growth (TTM YoY) | 5.5%
36th
|
15.9%
43rd
|
16.4%
50th
|
| Revenue growth (QoQ) | 2.5%
38th
|
3.9%
62nd
|
3.6%
56th
|
| Revenue CAGR, 3 yr | 11.7%
38th
|
14.9%
62nd
|
— |
| Revenue CAGR, 5 yr | 19.1%
85th
|
7.2%
31st
|
— |
| Gross profit CAGR, 3 yr | -60.7%
0th
|
3.6%
56th
|
— |
| Operating income CAGR, 3 yr | 12.1%
40th
|
31.7%
90th
|
— |
| Net income growth (TTM YoY) | 53.8%
62nd
|
82.3%
100th
|
— |
| Net income CAGR, 3 yr | -21.8%
0th
|
52.2%
75th
|
— |
| EPS growth (TTM YoY) | 55.5%
88th
|
74.8%
100th
|
— |
| EPS CAGR, 3 yr | -27.6%
0th
|
40.0%
62nd
|
— |
| EPS CAGR, 5 yr | -16.9%
0th
|
25.3%
100th
|
— |
| FCF growth (TTM YoY) | -76.2%
0th
|
15.9%
60th
|
71.0%
100th
|
| FCF CAGR, 3 yr | -31.5%
0th
|
15.0%
67th
|
— |
| Operating cash flow CAGR, 3 yr | 10.1%
40th
|
13.9%
70th
|
— |
| Book value CAGR, 3 yr | -1.6%
54th
|
5.0%
69th
|
— |
| Dividend CAGR, 3 yr | -7.4%
8th
|
-5.7%
23rd
|
— |
| Sustainable growth rate | -7.5%
25th
|
1.2%
75th
|
-1.9%
42nd
|
Margin history & stability
7 measures| Measure | DOC | OHI | AHR |
|---|---|---|---|
| Gross margin, 3-yr average | 40.8%
43rd
|
88.6%
93rd
|
16.8%
21st
|
| Operating margin, 3-yr average | 18.4%
50th
|
62.7%
100th
|
6.8%
0th
|
| Net margin, 3-yr average | 8.8%
50th
|
47.4%
93rd
|
1.0%
29th
|
| FCF margin, 3-yr average | 31.4%
50th
|
68.2%
93rd
|
6.4%
21st
|
| Revenue stability (0-1) | 0.98
100th
|
0.70
57th
|
0.91
79th
|
| Earnings stability (0-1) | 0.34
64th
|
0.58
93rd
|
0.57
86th
|
| Margin stability (0-1) | 0.46
29th
|
0.87
64th
|
0.65
43rd
|
Liquidity (latest quarter)
7 measures| Measure | DOC | OHI | AHR |
|---|---|---|---|
| Cash & short-term investments | $1.6B
94th
|
$39.0M
31st
|
$156.9M
69th
|
| Net cash (− = net debt) | −$8.7B
19th
|
−$4.0B
31st
|
−$1.4B
62nd
|
| Working capital | $1.1B
100th
|
−$32.7M
44th
|
−$725.1M
6th
|
| Current ratio | 2.52
82nd
|
0.91
64th
|
0.18
9th
|
| Quick ratio | 2.52
82nd
|
0.91
64th
|
0.18
9th
|
| Cash ratio (cash + ST investments / current liabilities) | 2.17
75th
|
0.11
25th
|
0.18
42nd
|
| Defensive interval (days) | — | 930 days
67th
|
698 days
44th
|
Leverage & solvency (latest quarter)
13 measures| Measure | DOC | OHI | AHR |
|---|---|---|---|
| Total debt | $10.3B
88th
|
$4.0B
69th
|
$1.6B
38th
|
| Debt / equity | 1.32
62nd
|
0.75
25th
|
0.42
6th
|
| Net debt / equity | 1.11
62nd
|
0.74
25th
|
0.38
6th
|
| Debt / assets | 47.6%
50th
|
40.0%
25th
|
27.5%
6th
|
| Debt / capital | 56.8%
62nd
|
42.7%
25th
|
29.8%
6th
|
| Debt / EBITDA | 5.79
44th
|
2.77
6th
|
3.76
19th
|
| Net debt / EBITDA | 4.88
31st
|
2.75
6th
|
3.38
19th
|
| Interest coverage (EBIT / interest) | 2.0x
69th
|
5.4x
88th
|
2.0x
62nd
|
| Cash interest coverage | 3.7x
69th
|
4.3x
75th
|
4.8x
88th
|
| Debt payback (years of OCF) | 8.4 yrs
69th
|
4.5 yrs
15th
|
4.2 yrs
8th
|
| Liabilities / assets | 56.2%
62nd
|
43.6%
25th
|
34.4%
12th
|
| IS credit model rating | BB+ | A- | BBB+ |
| Implied credit spread (bps) | 400
38th
|
175
6th
|
225
12th
|
Efficiency
11 measures| Measure | DOC | OHI | AHR |
|---|---|---|---|
| Asset turnover | 0.14
38th
|
0.13
25th
|
0.49
100th
|
| Fixed asset turnover | 7.47
75th
|
— | 0.55
50th
|
| Inventory turnover | — | — | — |
| Receivables turnover | 17.9
50th
|
4.8
14th
|
22.3
57th
|
| Days sales outstanding | 20 days
56th
|
77 days
88th
|
16 days
50th
|
| Days inventory outstanding | — | — | — |
| Days payables outstanding | 32 days
62nd
|
0 days
0th
|
6 days
56th
|
| Cash conversion cycle (days) | −12 days
25th
|
77 days
94th
|
10 days
62nd
|
| Capex / revenue | 31.7%
87th
|
— | 4.3%
47th
|
| Capex / depreciation | 0.85
87th
|
— | 0.41
73rd
|
| Operating expense ratio | 40.6%
75th
|
— | — |
Cash flow & earnings quality
7 measures| Measure | DOC | OHI | AHR |
|---|---|---|---|
| Operating cash flow / net income | 4.85
83rd
|
1.04
8th
|
3.05
75th
|
| FCF / net income | 1.17
25th
|
1.05
17th
|
2.16
67th
|
| FCF / operating cash flow | 24.1%
17th
|
— | 71.0%
33rd
|
| Capex / operating cash flow | 75.9%
83rd
|
— | 29.0%
67th
|
| Accruals ratio | -4.7%
50th
|
-0.3%
81st
|
-4.9%
44th
|
| Sloan accruals ratio | 2.7%
94th
|
-27.3%
6th
|
-10.2%
19th
|
| Earnings quality score (0-1) | 1.00
33rd
|
1.00
33rd
|
1.00
33rd
|
Scores & forensic checks
15 measures| Measure | DOC | OHI | AHR |
|---|---|---|---|
| IS score | 41
44th
|
69
94th
|
62
81st
|
| IS profitability | 37
50th
|
75
100th
|
13
19th
|
| IS growth | 60
29th
|
70
64th
|
69
57th
|
| IS value | 48
50th
|
57
81st
|
38
0th
|
| IS momentum | 88
50th
|
88
36th
|
95
79th
|
| IS risk (safety) | 15
12th
|
50
81st
|
80
88th
|
| IS quality | 67
62nd
|
76
81st
|
64
56th
|
| IS balance sheet | 45
75th
|
52
94th
|
45
69th
|
| IS earnings quality | 82
81st
|
72
56th
|
90
88th
|
| IS cash flow | 36
38th
|
75
62nd
|
65
56th
|
| Piotroski F-score (0-9) | 7
94th
|
6
50th
|
6
50th
|
| Altman Z-score | 1.0
44th
|
2.1
81st
|
3.0
88th
|
| Beneish M-score | −3.19
38th
|
−2.35
77th
|
— |
| Ohlson O-score | −7.99
38th
|
−8.71
12th
|
−8.70
19th
|
| IS credit score | 46
56th
|
68
94th
|
65
88th
|
Size (TTM)
8 measures| Measure | DOC | OHI | AHR |
|---|---|---|---|
| Market cap | $13.1B
81st
|
$13.8B
88th
|
$11.6B
75th
|
| Revenue | $2.9B
88th
|
$1.3B
56th
|
$2.5B
81st
|
| EBITDA | $1.8B
88th
|
$1.4B
81st
|
$417.4M
56th
|
| Net income | $253.7M
75th
|
$858.3M
94th
|
$121.0M
56th
|
| Free cash flow | $296.2M
69th
|
$903.3M
88th
|
$261.8M
62nd
|
| Total assets | $21.7B
88th
|
$10.0B
75th
|
$5.7B
56th
|
| Shareholders' equity | $7.8B
88th
|
$5.4B
81st
|
$3.7B
56th
|
| Employees | 411
60th
|
69
40th
|
121
47th
|
Price performance
9 measures| Measure | DOC | OHI | AHR |
|---|---|---|---|
| 1 day | +0.1% | +0.3% | +0.4% |
| 1 week | +1.0% | +2.8% | +4.8% |
| 1 month | −7.4% | −3.6% | +0.7% |
| 3 months | −14.8% | −6.7% | −6.0% |
| 6 months | +9.3% | −2.5% | +7.4% |
| Year to date | +18.6% | +4.1% | +12.7% |
| 1 year | +4.3% | +15.8% | +24.6% |
| 3 years, cumulative | +21.1% | +57.4% | — |
| 5 years, cumulative | −27.4% | +119.8% | — |
Technicals
4 measures| Measure | DOC | OHI | AHR |
|---|---|---|---|
| RSI 14 | 38.0 | 48.9 | 57.7 |
| From 52-week high | −17.3% | −11.7% | −9.3% |
| From 52-week low | +21.1% | +18.2% | +27.8% |
| Beta | 0.99 | 0.53 | 0.80 |
InsiderStreet reports findings from filings and market data. A comparison is not a recommendation to buy or sell either stock.Every figure is computed in code · data as of 2026-10-17